June 5, 2019
ASCO June 5 2019: Race and response to neoadjuvant chemotherapy
Raquel Nunes, Femke de Snoo, Lisette Stork-Sloots, Tina Treece, Christa Dreezen, William Audeh
Race and response to neoadjuvant chemotherapy according to MammaPrint risk
African-American (AA) women with breast cancer have a less favorable prognosis, likely due to differences in tumor biology. The Neoadjuvant BReast Cancer Symphony Trial (NBRST, NCT01479101) was a prospective trial that has shown an association of AA (150) MammaPrint/BluePrint (MP/BP) with a rate of pathologic Complete Response (pCR) of 2% pCR in Luminal A with 95% Distant Metastasis Free Interval at 3 yrs. Here, we determine the MP/BP risk 93% distribution, the response to therapy, and outcome in AA and Caucasian (Cau) patients.